Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Cheng Yong Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4424-2410; OpenAlex author ID A5061230439. Sources: OpenAlex.

Their work

Papers
10 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 5 papers · 2026: 1 paper

Papers 10

  1. IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. First author DOI 10.1016/j.gendis.2025.101866↗
  2. Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. First author DOI 10.1007/s10555-025-10297-9↗
  3. Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. First author DOI 10.1016/j.canlet.2025.217864↗
  4. Phthalocyanine and photodynamic therapy relieve albumin paclitaxel and gemcitabine chemoresistance in pancreatic cancer. First author DOI 10.1016/j.yexcr.2025.114455↗
  5. EDC4 enhances multi-drug chemosensitivity in pancreatic cancer via GR50-based profiling. Co-author DOI 10.1186/s12935-025-04000-9↗
  6. Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA. First author DOI 10.7150/jca.110659↗
  7. Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic st… Co-author DOI 10.1002/jev2.12488↗
  8. Circulating tumor cells in pancreatic cancer: more than liquid biopsy. First author DOI 10.1177/17588359241284935↗
  9. Retraction Note: IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Co-author DOI 10.1007/s13402-023-00897-4↗
  10. Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugs First author DOI 10.21203/rs.3.rs-1759071/v2↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bangbo Zhao · 10 shared papers, 2022–2026 · strength 2.36
  2. Zeru Li · 10 shared papers, 2022–2026 · strength 2.36
  3. Yutong Zhao · 8 shared papers, 2024–2026 · strength 2.02
  4. Tianyu Li · 6 shared papers, 2024–2026 · strength 1.52
  5. Weibin Wang · 6 shared papers, 2022–2025 · strength 1.35
  6. Weibin Wang · 4 shared papers, 2025–2026 · strength 1.01
  7. Haoyu Shi · 3 shared papers, 2025–2026 · strength 0.78
  8. Yiping Xie · 3 shared papers, 2025–2026 · strength 0.75
  9. Tianyu Li · 2 shared papers, 2022–2024 · strength 0.39
  10. Xiaoying Yang · 2 shared papers, 2022–2023 · strength 0.34
  11. Yuanyang Wang · 2 shared papers, 2022–2023 · strength 0.34
  12. Yuanyang Wang · 1 shared paper, 2025 · strength 0.27
  13. Yupei Zhao · 1 shared paper, 2024 · strength 0.23
  14. Xingtong Zhou · 1 shared paper, 2023 · strength 0.18
  15. Tianhao Li · 1 shared paper, 2023 · strength 0.18
  16. Tianhao Li · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.